Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Golberg AC, Brunham LR, Curcio D, Wuerdeman E, Neild A, Kling D, Hsieh R, Dicklin MR, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Davidson MH.
Nicholls SJ, et al. Among authors: golberg ac.
Am Heart J. 2024 May 4;274:32-45. doi: 10.1016/j.ahj.2024.05.002. Online ahead of print.
Am Heart J. 2024.
PMID: 38705341
Free article.